Compare MFIC & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MFIC | IVA |
|---|---|---|
| Founded | 2004 | 2011 |
| Country | United States | France |
| Employees | N/A | 77 |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | N/A | N/A |
| Metric | MFIC | IVA |
|---|---|---|
| Price | $11.72 | $5.51 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 10 |
| Target Price | $11.25 | ★ $16.20 |
| AVG Volume (30 Days) | ★ 1.3M | 345.9K |
| Earning Date | 05-06-2026 | 03-30-2026 |
| Dividend Yield | ★ 10.51% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,062.21 |
| P/E Ratio | $10.50 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.48 | $2.94 |
| 52 Week High | $13.51 | $7.98 |
| Indicator | MFIC | IVA |
|---|---|---|
| Relative Strength Index (RSI) | 63.43 | 46.25 |
| Support Level | $11.36 | $5.15 |
| Resistance Level | $11.74 | $6.50 |
| Average True Range (ATR) | 0.28 | 0.40 |
| MACD | 0.07 | -0.03 |
| Stochastic Oscillator | 85.15 | 44.87 |
MidCap Financial Investment Corp is an externally managed, publicly traded, closed-end, diversified management investment company. Its investment objective is to generate current income and, to a lesser extent, long-term capital appreciation. It predominantly invests in directly originated and privately negotiated first lien senior secured loans to privately held U.S. middle-market companies, and in other types of securities including, first lien unitranche, second lien senior secured, unsecured, subordinated, and mezzanine loans, and equities in both private and public middle market companies.
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.